Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680805 | 0.80 | MAPK1 (0.37) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL18889654 | 0.76 | CHRNB2 (0.38) | MAPK1L3MBTL1ALDH1A1MAPTKDM4E | |
| SCHEMBL6653610 | 0.73 | — | — | |
| SCHEMBL12170156 | 0.72 | MAOA (0.41) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL7492955 | 0.68 | CYP2D6 (0.36) | TDP1MAOAPOLB | |
| SCHEMBL24263827 | 0.66 | MAPT (0.36) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6864210 | 0.66 | FFAR1 (0.41) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6864215 | 0.66 | FFAR1 (0.41) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL12254378 | 0.66 | MAPK1 (0.49) | SLC18A3MAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL18250336 | 0.65 | MAOA (0.36) | MAPK1L3MBTL1ALDH1A1MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-2680861-B1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | NUTRITION 21 LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021084166-A1 | GOLD NANOSTRUCTURE COMPRISING ENZYMES AND ANTIOXIDANTS | BIO EVEN SAS (FR) | 2021-05-06 | — | — | WO | disclosed |
| CN-104758291-B | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2020-03-03 | — | — | CN | disclosed |
| EP-2292733-B1 | Production from blood of cells of neural lineage | KWALATA TRADING LTD (CY) | 2019-09-25 | — | — | EP | disclosed |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2019-06-20 | — | — | US | disclosed |
| EP-2427193-B1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORP (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9149469-B2 | Pharmaceutical composition and a process thereof | INDUS BIOTECH PVT. LTD. (IN) | 2015-10-06 | — | — | US | disclosed |
| EP-0770389-B1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA FARMACEUTICI (IT) | 2001-09-26 | — | — | EP | disclosed |
| EP-0770389-A1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA S.p.A. (IT) | 1997-05-02 | — | — | EP | disclosed |
| EP-0630250-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM 1? OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.p.A. (IT) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993017691-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM1 OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.P.A. (IT) | 1993-09-16 | — | — | WO | disclosed |
| US-5206226-A | Method of treatment of Parkinsons's disease using phytic acid | SABIN ROBERT (US) | 1993-04-27 | — | — | US | disclosed |
| US-5187162-A | Methods of treating neurodegenerative conditions | GENSIA PHARMACEUTICALS (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0491792-A4 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | — | 1992-12-02 | — | — | EP | disclosed |
| EP-0491792-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA, INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5112814-A | Method of treatment of Parkinson's disease using phytic acid | SABIN ROBERT (US) | 1992-05-12 | — | — | US | disclosed |
| WO-1991004032-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA PHARMACEUTICALS, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | SLC18A3 329/4885MAPK1 2183/4885L3MBTL1 590/4885 |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | SLC18A3 329/4885MAPK1 2183/4885L3MBTL1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.